BILLIONTOONE INC. A O.N.

BillionToOne reported a 64% revenue increase in the second quarter on a 35% rise in test volume and highlighted operating margins above 30% in the prenatal business. The oncology business grew 176% in the quarter and is becoming increasingly margin-accretive, even without full cost coverage. Management sees long-term growth in connecting large health systems but cautions about six- to 18-month integration timelines and excludes expected system gains and retroactive payments from its conservative outlook. The company signals high target gross margins at scale, is working on reimbursement and regulatory pathways (Medicare, ADLT/FDA), and is building a broad product pipeline in prenatal and oncology offerings. » More on de.investing.com

BTIG confirms BillionToOne as its top pick in the diagnostics sector, lowers the price target from $142 to $130, citing an 11.5x multiple on 2028 revenue expectations. BillionToOne reported Q2 revenue of $109.4m (+64% y/y) and reiterated full‑year guidance of $450–465m, but the stock fell 28% in after‑hours trading. The release was marked by declining true‑ups, a one‑time receivable delay of over $10m with a major payer, product updates (NorthStar Select expansion, UNITY roll‑out) and an expanded sales team. » More on de.investing.com

BillionToOne reported Q1 2026 revenue of $108.4m (+84% yoy) and earnings per share of $0.34, after a loss in the prior year. Gross margin was 73% and operating income turned to a profit of $17.8m. The new prenatal diagnostic product UNITY Confirm is expected to strengthen the portfolio, while the oncology business saw strong growth. After the results, the stock climbed about 16% in after-hours trading; management sees further EPS growth in coming quarters. » More on de.investing.com